Briakinumab.
BACKGROUND
Psoriasis is a chronic, autoimmune, T-cell mediated, inflammatory disease. An improved understanding of the pathogenesis of the autoimmune response has led to the development of targeted biologic therapies. Briakinumab is a human monocolonal antibody that blocks the activity of the cytokines IL-12 and IL-23. Immune dysregulation has been implicated in multiple inflammatory disorders and briakinumab has been investigated for the treatment of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.


OBJECTIVE
This review focuses on briakinumab and its use in chronic plaque-type psoriasis.


METHODS
A literature review was performed, searching Medline and the clinicaltrials.gov database for all articles with the keywords ABT-874, IL-12/IL-23 and psoriasis.


CONCLUSIONS
Although limited by small sample sizes, length of follow-up, and a lack of direct comparisons with other psoriasis treatments, initial data regarding the safety and efficacy of briakinumab for the treatment of psoriasis is promising. Ongoing Phase III trials may provide additional information regarding the relative efficacy and safety of briakinumab.
Lima
Xinaida Taligare
XT
Massachusetts General Hospital - Harvard Medical School, Boston, MA 02114, USA. xlima@partners.org
Abuabara
Katrina
K
Kimball
Alexandra Boer
AB
Lima
Hermenio Cavalcante
HC
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001691:Biological Therapy / Q000379:methods; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007249:Inflammation; D018664:Interleukin-12 / Q000378:metabolism; D053759:Interleukin-23 / Q000378:metabolism; D008954:Models, Biological; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D053759:Interleukin-23; D018664:Interleukin-12; C544528:briakinumab